Clinical Trials Sponsored by Japanese Foundation for Cancer Research

Total 5661 results

Swiss Group for Clinical Cancer Research

Completed

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

Metastatic Breast Cancer

France, Switzerland, Netherlands, Germany
Swiss Group for Clinical Cancer Research

Terminated

Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer

Colorectal Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Vinorelbine in Treating Patients With Metastatic Prostate Cancer

Prostate Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy

Breast Cancer

Switzerland, Belgium
Swiss Group for Clinical Cancer Research

Completed

Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC

Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy

Prostate Cancer

Switzerland
International Agency for Research on Cancer

Completed

Biomarkers of Processed Meat Intake

Biomarkers of Processed Meat Intake in Healthy Subjects

France
Swiss Group for Clinical Cancer Research

Terminated

Cetuximab for Elderly Patients With mCRC

Metastatic Colorectal Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Terminated

Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer

Liver Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal Cancer

Colorectal Cancer

Switzerland, Hungary
Swiss Group for Clinical Cancer Research

Completed

Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy

Leukemia

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain Metastases

Lung Cancer | Metastatic Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

Colorectal Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma

Lymphoma

Italy, Switzerland, Austria, Germany, Greece
Swiss Group for Clinical Cancer Research

Completed

Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy

Leukemia

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia

Leukemia

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia

Leukemia

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Combination Chemotherapy in Treating Patients With Advanced or Metastatic Colorectal Cancer

Colorectal Cancer

Switzerland
UNC Lineberger Comprehensive Cancer Center
Bristol-Myers Squibb; National Cancer Institute (NCI); National Center for Research... and other collaborators

Completed

Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer

Breast Cancer

United States
Swiss Group for Clinical Cancer Research

Not yet recruiting

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

Triple-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Recruiting

LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma (SAKK 38/23)

Non-hodgkin Lymphoma, B Cell

Switzerland
Swiss Group for Clinical Cancer Research

Active, not recruiting

Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

Leukemia | Chronic Lymphocytic Leukemia | Relapsed/Refractory Chronic Lymphocytic Leukemia

Switzerland
Swiss Group for Clinical Cancer Research

Terminated

ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

Prostate Cancer | Prostate Cancer Metastatic

France, Switzerland, Spain, Italy
Swiss Group for Clinical Cancer Research

Completed

Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients

Lung Cancer

Germany, Serbia, Switzerland
Swiss Group for Clinical Cancer Research

Active, not recruiting

1st Line Durvalumab in PS 2 NSCLC Patients

NSCLC Stage IV | NSCLC Stage IIIB

Switzerland
Duke University
Gateway for Cancer Research

Active, not recruiting

Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer

Breast Cancer

United States
Swiss Group for Clinical Cancer Research

Active, not recruiting

Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

Small Cell Lung Cancer | Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Active, not recruiting

Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. (SAKK 06/17)

Urothelial Cancer

Germany, Switzerland
Swiss Group for Clinical Cancer Research

Terminated

Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)

Squamous-cell Non-small Cell Lung Cancer

Switzerland
Ludwig Institute for Cancer Research
Medarex

Terminated

A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma

Synovial Sarcoma

United States
Swiss Group for Clinical Cancer Research

Terminated

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

Adenocarcinoma | Breast Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.

Lung Cancer | KRAS Gene Mutation | Advanced Non-small Cell Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Terminated

Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma (OptiPOM)

Refractory Multiple Myeloma

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Metformin Hydrochloride as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer

Prostate Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Biological Therapy in Treating Patients With Bladder Cancer

Bladder Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumor

France, Switzerland, Germany, Finland
Swiss Group for Clinical Cancer Research

Completed

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myeloproliferative Neoplasm

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer

Liver Cancer

Switzerland, Austria, Hungary
Swiss Group for Clinical Cancer Research

Completed

Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer

Breast Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

Malignant Mesothelioma

Switzerland, Germany
Swiss Group for Clinical Cancer Research

Completed

Metronomic Therapy in Metastatic Breast Cancer.

Breast Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma

Lymphoma

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Combination Chemotherapy Followed by Radiation Therapy Before Surgery in Treating Patients With Stage IIIB NSCLC

Lung Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Liver Cancer

Switzerland, Netherlands
Swiss Group for Clinical Cancer Research

Completed

PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Lymphoma

Switzerland, Italy
Swiss Group for Clinical Cancer Research

Withdrawn

Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents

Prostate Cancer

Switzerland
Swiss Group for Clinical Cancer Research

Completed

Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Lymphoma

France, Switzerland, Italy
Swiss Group for Clinical Cancer Research

Completed

Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

Switzerland
California Cancer Assocaties for Research & Excellence

Unknown

Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma

Metastatic Melanoma | Malignant Melanoma of Skin Stage III

United States

Clinical Trials Sponsored by Japanese Foundation for Cancer Research

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations